ArticleMicrobiology spectrum2026
Mitoxantrone synergies with tigecycline against
Xin Xia, Xiaoya Wei, Shuiping Chen, Zhihui Cheng, Yongxin Jin, Shouguang Jin, Weihui Wu
Abstract read
In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Xin XiaState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.ORCID 0009-0004-7775-2128 Xiaoya WeiState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.
Shuiping ChenDepartment of Laboratory Medicine, Fifth Medical Center of PLA General Hospital, Beijing, China.
Zhihui ChengState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.
Yongxin JinState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.ORCID 0000-0002-1449-6735 Shouguang JinState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.
Weihui WuState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China.ORCID 0000-0002-9017-0091 Funding
National Natural Science Foundation of China 32470193Science and Technology Committee of Tianjin 22JCZDJC00410
6 · The paper itselfAbstract
The global health threat of antimicrobial resistance necessitates the development of novel therapeutic strategies. This study identifies the anticancer agent mitoxantrone as a potent antimicrobial against
Indexed as
Anti-Bacterial AgentsKlebsiella InfectionsKlebsiella pneumoniaeMitoxantroneTigecyclineAnimalsBacterial ProteinsDrug SynergismHumansMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial ProteinsMitoxantroneTigecyclineKlebsiella pneumoniaemitoxantronetigecycline
Identifiers
PMID42584093
PMCPMC13532325
What OpenQuestion holds
Textmetadata
Read underepoch 390